The importance of serotonin and noradrenaline in anxiety

References

• Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47(6)577–85
   PubMed Web of Science ®Google Scholar
• Jenike MA. Obsessive-compulsive disorder: efficacy of specific treatments as assessed by controlled trials. Psychopharmacol Bull 1993; 29(4)487–99
   Google Scholar
• Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60(2)101–6
   PubMed Web of Science ®Google Scholar
• Fallon BA, Mathew SJ. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract 2000; 6(3)113–28
   Google Scholar
• Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs 2006; 20(9)763–90
   Google Scholar
• Lechin F, van der Dijs B, Hernandez-Adrian G. Dorsal raphe vs. median raphe serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological, neuropharmacological and clinical evidences: relevance for neuropharmacological therapy. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(4)565–85
   PubMed Web of Science ®Google Scholar
• Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71(4)533–54
   PubMed Web of Science ®Google Scholar
• Pineyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999; 51(3)533–91
   Web of Science ®Google Scholar
• Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17(5)343–62
   PubMed Web of Science ®Google Scholar
• Sanchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 2006; 99(2)91–5
   PubMed Web of Science ®Google Scholar
• Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005; 15(2)193–8
   PubMed Web of Science ®Google Scholar
• Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berlin) 2004; 174(2)163–76
   PubMed Web of Science ®Google Scholar
• El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacol 2005; 30(7)1269–77
   PubMed Web of Science ®Google Scholar
• Hensler JG. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 2003; 72(15)1665–82
   PubMed Web of Science ®Google Scholar
• Riiad M, Zimmer L, Rbah L, Watkins KC, Hamon M, Descarries L. Acute treatment with the antidepressant fluoxetine internalizes 5-HT1A autoreceptors and reduces the in vivo binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rats. J Neurosci 2004; 24(23)5420–6
   Google Scholar
• Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003; 45(2)167–73
   PubMed Web of Science ®Google Scholar
• Sanchez C, Gruca P, Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 2003; 14(5–6)465–70
   Google Scholar
• El Mansari M, Bouchard C, Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacol 1995; 13(2)117–27
   PubMed Web of Science ®Google Scholar
• El Mansari M, Blier P. Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. J Psychiatry Neurosci 2005; 30(4)268–74
   Google Scholar
• Bergqvist PB, Bouchard C, Blier P. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biol Psychiatry 1999; 45(2)164–74
   Google Scholar
• Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci 2001; 26(Suppl)S3–10
   PubMedGoogle Scholar
• Szabo ST, de Montigny C, Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2000; 3(1)1–11
   PubMed Web of Science ®Google Scholar
• Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986; 43(11)1042–54
   Google Scholar
• Coplan JD, Papp LA, Pine D, et al. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry 1997; 54(7)643–8
   Google Scholar
• Dremencov E, El Mansari M, Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 2007; 61(5)671–8
   PubMed Web of Science ®Google Scholar